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Introduction 
Diabetic nephropathy (DN), the major microvascular complica-
tion of  diabetes mellitus (DM), remains the leading cause of  in-
creased morbidity and mortality for diabetic patients [1, 2]. The 
pathogenesis of  DN is multifactorial and it has been considered 
to involve metabolic factors [renal polyols [3-6], advanced glyca-
tion end products (AGEs) [7-11]), hemodynamic factors (angio-
tensin II [12], endothelin I [4]), and oxidative stress [13], orches-
trated by genetic and environmental factors. Moreover, recent 
evidence suggests that chronic subclinical inflammation is a key 
pathogenetic mechanism in the development and progression of  
diabetic nephropathy [14]. Although the form and severity of  
glomerular lesions vary widely in DN, tubulointerstitial infiltra-
tion by mononuclear cells and T lymphocytes is a common histo-
logic finding, even at early stages of  the disease. Tubulointerstitial 
infiltration can result from several metabolic and hemodynam-
ic factors and oxidative stress. The above lead to activation of  
protein kinase cascade and transcription factors, such as nuclear 
factor-κB (NFκB) [14, 15], that initiate cell signalling pathways 
on glomerular and tubulointerstitial cells. The consequent pro-
duction of  inflammatory mediators, including pro-inflammatory 
cytokines,  chemokines, and growth factors and the up-regulation 
of  adhesion molecules on both leukocytes and endothelial cells, 
result in the initiation of  a vicious cycle that eventually results 
in the development of  glomerulosclerosis and tubulointerstitial 
fibrosis [14-16].
In 1991 Hasegawa et al. first suggested that pro-inflammatory cy-
tokines could participate in the development of  DN. The authors 
demonstrated that macrophages incubated with glomerular base-
ment membranes from diabetic rats produced greater amounts of  
interleukin (IL) -1 and tumor necrosis factor (TNF) -α compared 
to macrophages incubated with membranes from normal rats. 
Production of  these cytokines was probably induced by AGEs, 
as it was reduced after treatment with aminoguanidine, an AGE 
accumulation inhibitor [17]. Subsequently, accumulating evidence 
from experimental and clinical studies suggested that inflamma-
tion plays a key role in the pathogenesis of  diabetic nephropathy. 
As a result, several inflammatory markers have been investigated 
as prognostic factors of  disease development and as markers of  
disease severity.
C-reactive protein
C-reactive protein (CRP) is an acute phase protein, produced by 
the liver after stimulation by pro-inflammatory cytokines, includ-
ing IL-1, IL-6 and TNF-α. CRP is considered to have several char-
acteristics that play a key role in natural host defense. Specifically, 
CRP is a member of  the pentraxin family of  oligomeric proteins 
which are involved in innate immunity. Immunoregulatory func-
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tions of  CRP that lead to evolution of  renal impairment include 
leukocyte migration, complement activation, platelet function 
regulation and clearance of  cellular debris from sites of  active 
inflammation [18]. There has been substantial experimental evi-
dence and recent findings from clinical studies suggesting that 
CRP is a sensitive marker of  subclinical inflammation, which is 
associated with insulin resistance, metabolic syndrome, hypergly-
cemia and Type 2 diabetes mellitus (DM) [18].
To the best of  our knowledge, only few studies have investigated 
the association between albuminuria and CRP in diabetic patients, 
and results were controversial. In our recently published study, we 
did not observe any difference in CRP levels between normo- and 
micro-albuminuric patients and, moreover, no significant correla-
tion was noted between severity of  micro-albuminuria and CRP 
levels [19]. In agreement with our results, Choudhary and Ahla-
wat found that although CRP values were higher in patients with 
macro-albuminuria and they were positively correlated with the 
degree of  albuminuria, no significant difference was observed 
between normo-albuminuric and micro-albuminuric diabetic pa-
tients [20]. Similarly, other investigators reported elevated CRP 
levels in diabetics either with or without microangiopathy com-
pared to healthy controls, but no difference between normo- and 
micro-albuminuric diabetic patients [21-24]. In contrast to the 
above findings, some studies have shown that CRP levels can 
discriminate diabetic patients with normo-, micro- and macro-
albuminuria [25, 26].  Finally, a recent prospective cohort study 
in Japan, which included 2,518 patients with Type 2 DM, demon-
strated that elevated CRP levels were associated, independently 
of  possible confounders, with a subsequent risk of  developing 
(normo- to micro-albuminuria), but not progressing, diabetic ne-
phropathy (micro- to macro-albuminuria) [27]. Overall, the find-
ings of  the reports up-to now suggest that classic inflammatory 
markers are mainly increased in patients with overt nephropathy 
and macro-albuminuria, which is probably associated with sys-
temic activation of  the inflammatory response.
Tumor necrosis factor-α
TNF-α is a functional transmembrane homotrimeric protein that 
is produced by many cell types, including leukocytes, adipocytes 
and endothelial cells [24]. TNF-α is cleaved from the cell surface 
by a disintegrin and mettaloprotease protein-17 (ADAM-17) and 
it is released into circulation as a functional 17kDa soluble form. 
TNF-α acts through its receptors, TNF receptor 1 (TNFR1) and 
TNF receptor 2 (TNFR2). In plasma, TNF-α may be either free, 
or bound to circulating TNF-R1 and TNF-R2 [24, 28, 29]. Gly-
cosylated forms of  both receptors have been found in the urine 
[24, 28]. In response to stimulating factors, such as lipopolysac-
charide, IL-1α and during inflammation, TNF-α and its recep-
tors are expressed by activated native kidney cells (glomerular 
mesangial, epithelial and endothelial cells, and tubular epithe-
lial cells) and monocytes-macrophages [30-32]. As a result, they 
stimulate the production of  other cytokines (IL-8), acute phase 
proteins, growth factors and chemokines [monocyte chemoat-
tractant protein (MCP)-1, and macrophage-colony stimulating 
factor (M-CSF)] by adjacent cells [23, 30]. Moreover, TNF-α up-
regulates the expression of  adhesion molecules on leukocytes and 
endothelial cells that mediate adhesion of  monocytes, lympho-
cytes, and granulocytes to activated endothelium and their subse-
quent migration [30, 33]. Since TNF-α is a pleiotropic cytokine, 
it exerts multiple effects that may promote renal damage in dia-
betic nephropathy through several mechanisms. It can cause va-
soconstriction and reduction of  glomerular blood flow through 
the production of  endothelin-1. It interacts with the intracellular 
junctions of  the glomerular filtration barrier and disrupts them 
increasing its permeability and resulting in the development of  
albuminuria [30, 34]. Increased production of  TNF-α can also 
produce oxidative stress, through the activation of  nicotinamide 
adenine dinucleotide phosphate (NADPH) in mesangial cells. Fi-
nally, TNF-α appears to have a direct apoptotic and cytotoxic ef-
fect on glomerular cells [30, 35].
Some experimental and clinical studies investigated the probable 
associations between serum or/and urine TNF-α levels with the 
development and progression of  DN and with the severity of  
disease. Navarro et al. and Nakamura et al. reported increased 
expression of  TNF-α mRNA in the glomeruli of  diabetic com-
pared to non- diabetic mice [36, 37]. In addition, Nakamura et al. 
reported a significant correlation between urinary albumin excre-
tion and urinary TNF-α levels, as well as renal TNF-α expression. 
Of  note, administration of  an angiotensin enzyme inhibitor, enal-
april, nearly completely abolished the increase in TNF-α mRNA 
expression to the level observed in control rats and decreased 
urinary cytokine excretion and albuminuria. The above data sup-
ported the hypothesis that inflammatory mechanisms may play 
a significant role in the development and progression of  renal 
injury secondary to diabetes mellitus. In another experimental 
study, interstitial expression and urinary excretion of  TNF-α were 
increased early in the course of  the disease and preceded the rise 
in urinary albumin excretion (UAE) by about 2 weeks. Moreover, 
a second significant increase was observed after the onset of  al-
buminuria, suggesting that this cytokine has an important role in 
the pathogenesis and progression of  diabetic nephropathy, but its 
production is farther increased by albuminuria [38].
Recent studies in diabetic patients have demonstrated a correla-
tion between urinary TNF-α levels and the presence and severity 
of  albuminuria. We and others have shown that micro-albuminu-
ric patients had significantly increased urinary TNF-α concentra-
tions compared to normo-albuminuric patients and normal con-
trol subjects [19, 39]. In addition, we have recently demonstrated 
that urinary TNF-α levels are significantly and independently as-
sociated with the severity of  micro-albuminuria [19]. Moreover, 
some studies suggested that TNF-α is predominantly involved in 
the progression of  albuminuria during the early stages of  diabetic 
nephropathy. Wu et al., [40] measured baseline levels of  urinary 
TNF-α in 63 non-diabetic controls and 201 patients with Type 2 
diabetes and different degrees of  albuminuria and subsequently 
followed-up them for 28 months, with routine measurements 
of  creatinine and UAE. The results showed that baseline uri-
nary levels TNF-α were significantly elevated and correlated with 
the severity of  albuminuria in patients with diabetes. During the 
follow-up, urinary TNF-α levels were found to be significantly 
associated with a rapid decline in the estimated glomerular filtra-
tion rate (eGFR) and the above correlation remained significant 
following adjustment for other progression promoters, including 
albuminuria, Similarly, Verhave et al. reported a correlation be-
tween urinary TNF-α levels and the rate of  renal function decline 
in patients with diabetes Type 2 and macro-albuminuria during a 
median 2.1 years follow-up; however, the above association lost 
significance in the multivariate model [41]. Overall, these results 
suggested that inflammation is important in the pathogenesis of  
DN and indicated that TNF-α may be used as an independent 
predictor for the progression of  DN at the early stage. Finally, in 
a very recently published prospective, randomized trial, adminis-
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tration of  pentoxifylline, in addition to renin-angiotensin system 
blockade, has been shown to further decrease proteinuria and to 
slow progression of  renal disease in patients with Type 2 diabetes 
and stages 3-4 CKD during the 2 year follow-up period. In addi-
tion, pentoxifylline administration, was  associated with decrease 
of  urinary TNF-α levels whereas the latter remained unchanged 
in the control group [42].
Although undoubtedly there is an association between urinary 
TNF-α levels and the severity and progression of  diabetic ne-
phropathy, the probable value of  serum TNF-α levels remains 
controversial. Navarro-González et al. reported a correlation be-
tween serum TNF-α levels and albuminuria [22]. In our study, 
however, no significant correlation was observed between the 
severity of  micro-albuminuria and serum TNF-α levels. Moreo-
ver, and in agreement with the previous study, no correlation was 
observed between serum and urinary TNF-α levels, suggesting 
mainly intrarenal production of  this cytokine and therefore local 
and non-systemic activation of  the inflammatory response [22, 
19]. The above hypothesis is further supported by the lack of  
correlation between micro-albuminuria and CRP, fibrinogen and 
serum TNF-α levels in our patients [19]. Finally, Niewczas et al. 
in the Joslin Kidney Study found that the risk- incidence rate of  
end-stage renal disease during 8 to 12 years follow-up was associ-
ated with elevated plasma concentrations of  free and total plasma 
TNF-α levels, at baseline [29].
Despite extensive research, there are still unanswered questions 
regarding the implication of  TNF-α in the initiation of  inflam-
matory cascade and the pathogenesis of  renal damage in diabe-
tes mellitus [22, 35, 37, 38]. A hypothesis of  activation of  local 
inflammatory pathways in association with increased production 
and excretion of  TNF-α, may provide an explanation of  kidney 
damage at the early stages of  diabetic nephropathy. In more ad-
vanced stages, a systemic inflammatory response may be activated 
and lead to the development of  several micro-and macrovascular 
complications.
Tumor necrosis factor receptors
TNFR1 and TNFR2 are single transmembrane glycoproteins 
which belong to the TNF-α receptor superfamily and are referred 
to as markers of  the TNF pathway. TNFR1 and TNFR2 have a 
molecular weight of  55 and 75 kDa respectively and are products 
of  separate genes [43].
TNFR1 can be detected in all cell types, while TNFR2 is only 
expressed by oligodendrocytes, astrocytes, myocytes, thymocytes, 
endothelial cells, T lymphocytes and human mesenchymal stem 
cells. In kidney and under physiological conditions, TNF-α and 
TNFR2 are usually not present, whereas TNFR1 can be found 
in normal glomerular endothelium and is primarily localized 
within the Golgi apparatus [32, 43]. During inflammation and in 
response to stimulating factors, such as lipopolysaccharides and 
IL-1α, TNFR1 and TNFR2, are expressed in activated native kid-
ney cells (glomerular mesangial, epithelial and endothelial cells, 
and tubular epithelial cells) and also in activated monocytes-mac-
rophages [14, 16, 43]. Expression of  TNFR2 is essential for the 
action of  TNFR1. TNFR2 is a pro-inflammatory mediator which 
promotes cell migration, regeneration and proliferation and also 
enhances the role of  TNFR1 by increasing the concentration of  
TNF-α available to TNFR1. TNFRs are cleaved from the cell 
surface by a disintegrin and metalloprotease protein-17 (ADAM-
17), which results in the soluble forms of  TNFRs [32].  There is 
a disagreement whether the soluble circulating levels of  TNFRs 
are more important than the cellular signal transduction through 
these receptors. Moreover, mechanisms that regulate TNFRs have 
not been yet clarified although TNF-α was suggested to be the 
main regulating factor that induces shedding of  TNFRs. How-
ever, this theory has not been confirmed in diabetic patients and 
definitely further investigation is required on the factors that in-
fluence the concentration and the role of  TNFRs. Of  note, serum 
levels of  TNFRs are 100-500 times higher than those of  TNF-α, 
which implies an additional role for TNFRs, besides that of  bind-
ing TNF-α [43].
Recent studies in diabetic patients have shown that elevated con-
centrations of  circulating TNFRs were strongly associated with 
renal function during follow-up but not with the presence or se-
verity of  albuminuria. Lin et al. studied eGFR decline over 11 
years in 516 women with Type 2 diabetes mellitus in the Nurses' 
Health Study. Comparing the highest with the lowest quartile, sol-
uble TNFR2 levels were independently associated with an eGFR 
decline of  > or = 25%  and this association was stronger in obese 
women. Of  note, no lipids and other markers of  inflammation 
(CRP, fibrinogen, E-selectin, intercellular adhesion molecule 1, 
leptin or adiponectin) were significantly associated with eGFR 
decrease after multivariable adjustment [44]. More recently, in the 
aforementioned study of  Niewczas et al. the risk of  end-stage 
renal disease during the 8 to 12 years of  follow-up was strongly 
associated with elevated baseline plasma concentrations of  circu-
lating TNFR1 and TNFR2 [29]. This correlation was evident in 
both proteinuric and non-proteinuric patients and remained sig-
nificant after adjustment for clinical covariates including urinary 
albumin excretion. As we mentioned above, free and total plasma 
TNF-α levels also tended to predict progressive nephropathy, but 
less significantly than their receptor levels [29]. In addition, a very 
recent study in American Indians reported that baseline TNFRs 
levels were associated with the risk of  end-stage renal disease 
defined as dialysis, kidney transplant, or death attributed to dia-
betic kidney disease during a median follow-up of  9.5 years after 
adjusting for age, gender, mean blood pressure, HbA1c, urinary 
albumin-to-creatinine ratio, and measured by iothalamate GFR 
[45]. In addition, in Japanese Type 2 diabetic patients without 
overt proteinuria baseline serum levels of  soluble TNFR1 and 
TNFR2 were found to predict a greater decline in eGFR rate after 
5 years. Moreover, patients with high level of  both TNFR1 and 
TNFR2 showed a 4-fold higher risk for a GFR decline of  ≥ 25% 
than those with high level of  only one receptor or low level of  
both receptors and these associations were enhanced in diabetic 
women [46]. Of  note, Fernandez-Real et al. in patients with Type 
2 diabetes and normo- or micro-albuminuria demonstrated a cor-
relation between soluble TNFR1, but not TNFR2, and mesangial 
expansion in renal biopsies which remained significant after con-
trolling for age, body mass index and blood pressure. In contrast, 
albumin excretion rate was not significantly associated with either 
mesangial expansion or TNFR1 and TNFR2 levels [47]. Elevated 
plasma concentrations of  TNFRs have been also shown to pre-
dict stage 3 CKD among patients with Type 1 diabetes. Gohda et 
al. followed two cohorts comprising 628 patients with Type 1 dia-
betes, normal renal function, and no proteinuria for over 12 years. 
Concentrations of  TNFR1 and TNFR2 were found to be strong-
ly associated with risk for early renal decline (eGFR less than 60 
ml/min per 1.73 m2). The risk associated with high TNFR1 values 
was slightly less than that associated with high TNFR2 values. 
TNFR levels were unrelated to baseline free TNF-α level and re-
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mained stable over long periods within an individual. Moreover, 
renal decline was associated only modestly with total TNF-α con-
centration and appeared unrelated to free TNF-α [48]. 
Overall the findings of  the studies up-to-now suggested that 
measurement of  serum TNFR levels may identify diabetic patients 
on high- risk of  declining renal function but also raised questions 
on the importance of  micro-albuminuria to the pathogenesis of  
renal dysfunction in Type 2 DM. Of  note, an interesting recent 
experimental study investigated whether TNF-α inhibition with 
a soluble TNFR2 fusion protein, etanercept, improves the early 
stage of  DN in the Type 2 diabetic model of  the KK-A(y) mouse 
and also which TNF pathway, TNFR1 or TNFR2, is predomi-
nantly involved in the progression of  this disease [49]. Admin-
istration of  etanercept was associated with a dramatic improve-
ment of  albuminuria but also of  glycemic control. Renal mRNA 
and/or protein levels of  TNFR2, but not TNF-α and TNFR1, 
in etanercept-treated mice were significantly decreased compared 
with untreated mice. Finally, mRNA levels of  intercellular adhe-
sion molecule-1, vascular cell adhesion molecule-1, and mono-
cyte chemoattractant protein-1 and the number of  macrophages 
were all decreased after treatment. The above results indicated 
that etanercept may improve the progression of  the early stage 
of  diabetic nephropathy predominantly through inhibition of  the 
pro-inflammatory action of  the TNF-α-TNFR2 pathway [49].
Conclusion
Diabetic nephropathy remains the leading cause of  increased 
morbidity and mortality and an urgent need exists to identify nov-
el biomarkers and to develop new therapeutic strategies. However, 
identification of  diabetic patients at high risk of  developing pro-
gressive nephropathy is a challenge considering the complexity of  
the multiple pathophysiological processes involved in the devel-
opment and progression of  the disease. Recent evidence suggests 
that inflammation plays a key role in the disease and accordingly 
the probable value of  several inflammatory biomarkers as predic-
tors of  disease development and progression is under investiga-
tion, Among them TNF-α appeared to play a key role in the de-
velopment of  albuminuria and TNF-α-TNFR signaling pathways 
emerged as promising predictors of  renal function decline. How-
ever, the value of  these biomarkers should be examined in large, 
prospective, multicenter trials with long-term follow-up period 
in order to determine their usefulness in daily clinical practice. 
Moreover, although several ways of  specifically manipulating the 
TNF superfamily system already exist, whether or not these drugs 
provide new targets for intervention and more effective treatment 
options for diabetic patients is still to be revealed.
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